# AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

> **NCT00395967** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** G-CSF plus plerixafor

## Key facts

- **NCT ID:** NCT00395967
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2005-07
- **Final completion:** 2006-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Enrollment terminated in 2005 to focus on Phase 3 study enrollment.
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395967, "AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00395967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*